Araujo-Castro M,Berrocal VR,Pascual-Corrales E .2020 .Pituitary tumors: Epidemiology and clinical presentation spectrum. Hormones (Athens), 19(2) : 145-155.
Bonneville JF,Potorac J,Beckers A .2020 .Neuroimaging of aggressive pituitary tumors. Rev. Endocr. Metab, 21(2) : 235-242.
Fiori V,Magnani M,Cianfriglia M M .2012 .The expression and modulation of CEACAM1 and tumor cell transformation. , 48(2) : 161-71.
Gheorghe G,Diaconu CC,Mambet C,Bleotu C,Ionescu VA,Diaconu CC .2024 .Comparative analysis of leptin and carcinoembryonic antigen-related cell adhesion molecule 1 plasma expression in pancreatic cancer and chronic pancreatitis patients. , 10(17) : e37410.
Götz L,Rueckschloss U,Najjar SM,Ergun S,Kleefeldt F S,Clin S .2024 .Carcinoembryonic antigen-related cell adhesion molecule 1 in cancer: Blessing or curse? Eur. , 25 : e14337.
He Y,Yuan Y,Ji L,Shu Y,Wang Z,Zhang S,Yang W,Chen M,Liu Y .2024 .Integrative analysis identifies NSUN2 as an essential coordinator for glioma malignancy and glucose metabolism. J. Gene. Med, 26(12) : e70004.
Huang YH,Yoon CH,Gandhi A,Hanley T,Castrillon C,Kondo Y,Lin X,Kim W,Yang C,Driouchi A,Carroll M,Gray-Owen SD,Wesemann DR,Drake CG,Bertagnolli MM,Beauchemin N,Blumberg RS .2024 .High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistance. Commun. Med, 4(1) : 128.
Iglesias P,Magallón R,Mitjavila M,Rodríguez Berrocal V,Pian H,Diez JJ H .2020 .Multimodal therapy in aggressive pituitary tumors. Endocrinol. Diabetes Nutr, 67(7) : 469-485.
Jeon SH,Kang M,Jeon M,Chung Y,Kim AR,Lee YJ,Kim ES,Nam H,Park J,Lee JY,Shin EC,Seo SI,Park SH .2023 .CEACAM1 marks highly suppressive intratumoral regulatory T cells for targeted depletion therapy. Clin. Cancer Res., 29(9) : 1794-1806.
JKonieva A,Deineka V,Diedkova K,Aguilar-Ferrer D,Lyndin M,Wennemuth G,Korniienko V,Kyrylenko S,Lihachev A,Zahorodna V,Baginskiy I,Coy E,Gogotsi O,Blacha-Grzechnik A,Simka W,Kube-Golovin I,Iatsunskyi I,Pogorielov M .2024 .MXenePolydopamine-antiCEACAM1 antibody complex as a strategy for targeted ablation of melanoma. ACS Appl. Mater. Interfaces, 16(33) : 43302-43316.
Liu W .2022 .Serum Level of CEACAM1 in patients with nonsmall cell lung cancer and its clinical significance in cancer tissue. J. Healthc. Eng., 7948010 : .
Markel G,Seidman R,Cohen Y,Besser MJ,Sinai TC,Treves AJ,Orenstein A,Berger R,Schachter J .2009 .Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology, 126(2) : 186-200.
Marrero-Rodríguez D,Taniguchi-Ponciano K,Kerbel J,Cano-Zaragoza A,Remba-Shapiro I,Silva-Román G,Vela-Patiño S,Andonegui-Elguera S,Valenzuela-Perez A,Mercado M .2023 .The hallmarks of cancer… in pituitary tumors? Rev. , 24(2) : 177-190.
Matsumoto H,Sudo R,Fujita Y,Onizawa M,Saito K,Sumichika Y,Yoshida S,Temmoku J,Matsuoka N,Asano T,Sato S,Suzuki E,Machida T,Migita K .2024 .Inhibition of CEACAM1 expression in cytokine-activated neutrophils using JAK inhibitors. BMC Immunol, 25(1) : 63.
Muturi HT,Ghadieh HE,Asalla S,Lester SG,Verhulst S,Stankus HL,Zaidi S,Abdolahipour R,Belew GD,Grunsven LA,Friedman SL,Schwabe RF,Hinds TD,Najjar SM .2024 .Conditional deletion of CEACAM1 causes hepatic stellate cell activation. Update in: Mol. Metab, 88 : 102010.
Rao V,Kumar G,Vibhavari RJA,Nandakumar K,Thorat ND,Chamallamudi MR,Kumar N MR .2023 .Temozolomide resistance: A multifarious review on mechanisms beyond O-6-Methylguanine-DNA methyltransferase. CNS Neurol. Disord. Drug Targets, 22(6) : 817-831.
Sauer N,Janicka N,Szlasa W,Skinderowicz B,Kołodzińska K,Dwernicka W,Oślizło M,Kulbacka J,Novickij V,Karłowicz-Bodalska K .2023 .TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol, 72(11) : 3405-3425.
Schwartz LH,Litière S,de Vries E,Ford R,Gwyther S,Mandrekar S,Shankar L,Bogaerts J,Chen A,Dancey J,Hayes W,Hodi FS,Hoekstra OS,Huang EP,Lin N,Liu Y,Therasse P,Wolchok JD,Seymour L JD .2016 .. RECIST 1.1-Update and clarification: From the RECIST Committee. Eur. J. Cancer, 62 : 132-137.
Southekal S,Shakyawar SK,Bajpai P,Elkholy A,Manne U,Mishra NK,Guda C .2023 .Molecular subtyping and survival analysis of osteosarcoma reveals prognostic biomarkers and key canonical pathways. Cancers (Basel), 15(7) : 2134.
Spada A,Mantovani G,Lania AG,Treppiedi D,Mangili F,Catalano R,Carosi G,Sala E,Peverelli E .2022 .Pituitary tumors: Genetic and molecular factors underlying pathogenesis and clinical behavior. J. Neuroendocrinol., 112(1) : 15-33.
Tang R,Lin W,Shen C,Hu X,Yu L,Meng T,Zhang L,Eggenhuizen PJ,Ooi JD,Jin P,Ding X,Xiao X,Zhong Y,Pt A .2023 .Single-cell transcriptomics uncover hub genes and cell-cell crosstalk in patients with hypertensive nephropathy. Int. Immunopharmacol., 111104 : .
Toader C,Bratu BG,Mohan AG,Bentia D,Ciurea AV D .2023 .Comparison of transcranial and transsphenoidal approaches in intra and suprasellar pituitary adenomas - systematic review. Acta Endocrinol (Buchar), 19(2) : 228-233.
Tritos NA,Miller KK .2023 .Diagnosis and management of pituitary adenomas: A review. JAMA, 329(16) : 1386-1398.
Veleno M,Giampietro A,Raia S,Menotti S,Tartaglione T,Gaudino S,Doglietto F,DE Marinis L,Pontecorvi A,Chiloiro S,Bianchi A .2024 .Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients. Minerva Endocrinology, 49(3) : 269-282.
Yi E,Go J,Yun SH,Lee SE,Kwak J,Kim SW,Kim HS .2024 .CEACAM1-engineered MSCs have a broad spectrum of immunomodulatory functions and therapeutic potential via cell-to-cell interaction. Biomaterials, 311 : 122667.
Yu J,Cai W,Zhou T,Men B,Chen S,Tu D,Guo W,Wang J,Zhao F,Wang Y .2024 .CEACAM1 increased the lymphangiogenesis through miR-423-5p and NFkB in non-small cell lung cancer. Biochem. Biophys. Rep, 40 : 101833.
Zhang B,Liu R,Huang H,Wang C,Yang C .2024 .Identifying CEACAM1 as a potential prognostic biomarker for basal-like breast cancer by bioinformatics analysis and in vitro experiments. J. Cancer, 15(19) : 6468-6478.
Zhao L,Li T,Zhou Y,Wang P,Luo L P .2024 .. , : .